Does Rallies show 13F holders for EYPT?

Yes. Rallies tracks hedge fund and 13F ownership data for EYPT, including fund names, share counts, latest tracked quarter, and position changes when available.

Is EYPT research on Rallies investment advice?

No. Rallies provides research, data, and educational context for EYPT. It does not provide personalized investment advice.

EYPT (EyePoint, Inc. Common Stock) Stock Analysis - Hedge Fund Holdings

EyePoint, Inc. Common Stock (EYPT) is a publicly traded Healthcare sector company. As of May 21, 2026, EYPT trades at $12.54 with a market cap of $980.94M and a P/E ratio of -3.95. EYPT moved +5.92% today. Year to date, EYPT is -28.28%; over the trailing twelve months it is +101.29%. Its 52-week range spans $3.91 to $19.11. Analyst consensus is strong buy with an average price target of $36.40. Rallies surfaces EYPT's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who owns EYPT stock?

Hedge funds tracked by Rallies that own EYPT include Orbimed Advisors and Panagora Asset. The latest tracked quarter is Mar 31, 2026. Rallies shows current holdings, share counts, position changes, and 13F ownership context for EyePoint, Inc. Common Stock.

EYPT Key Metrics

Key financial metrics for EYPT
Metric	Value
Price	$12.54
Market Cap	$980.94M
P/E Ratio	-3.95
EPS	$-3.17
Dividend Yield	0.00%
52-Week High	$19.11
52-Week Low	$3.91
Volume	7.91K
Avg Volume	0
Revenue (TTM)	$31.37M
Net Income	$-231.96M
Gross Margin	0.00%

Top Hedge Funds Holding EYPT

Orbimed Advisors holds 1.07M shares of EYPT, changed -56.69% as of Mar 31, 2026.
Panagora Asset holds 132.21K shares of EYPT, changed +0.00% as of Mar 31, 2026.

Latest EYPT News

EyePoint’s DURAVYU Phase 3 Trials Secure Third DSMC Review with 35% Third Dose — May 14, 2026
EyePoint Posts $84.8M Q1 Loss, Holds $223M Cash for Mid-2026 Readouts — May 6, 2026
EyePoint Raises $306M Runway, Phase 3 DME Dosing and Mid-2026 Wet AMD Data — Mar 4, 2026
EyePoint Secures $300M Cash Runway into Q4 2027, Phase 3 DURAVYU Trials On Track — Mar 4, 2026
EyePoint Appoints Veteran Commercial Leader with 175,000 Options for DURAVYU Phase 3 Launch — Feb 18, 2026

Recent EYPT Insider Trades

Ribeiro Ramiro sold 2.44K (~$36.55K) on Apr 17, 2026.
Duker Jay S. bought 1.50K (~$19.72K) on Mar 16, 2026.
Ribeiro Ramiro sold 2.44K (~$43.57K) on Mar 4, 2026.

EYPT Analyst Consensus

10 analysts cover EYPT: 0 strong buy, 10 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $36.40.

Common questions about EYPT

Who owns EYPT stock?: Hedge funds tracked by Rallies that own EYPT include Orbimed Advisors and Panagora Asset. The latest tracked quarter is Mar 31, 2026. Rallies shows current holdings, share counts, position changes, and 13F ownership context for EyePoint, Inc. Common Stock.
Does Rallies show 13F holders for EYPT?: Yes. Rallies tracks hedge fund and 13F ownership data for EYPT, including fund names, share counts, latest tracked quarter, and position changes when available.
Is EYPT research on Rallies investment advice?: No. Rallies provides research, data, and educational context for EYPT. It does not provide personalized investment advice.